Faculty of Nursing (Cuthbert, Daze, Farrer) and Department of Oncology, Cumming School of Medicine (Cuthbert, Nixon, Karim, Cheung), University of Calgary; Cancer Care Alberta (Nixon, Rawson, Karim, Cheung) and Patient and Family Engagement Advisory Network for Cancer Care Alberta (Laxdal, Huband), Alberta Health Services, Calgary, Alta.; Patient and Family Engagement Advisory Network for Cancer Care Alberta (Dundas), Alberta Health Services, Drumheller, Alta.; The Ottawa Hospital (Vickers) and University of Ottawa (Vickers), Ottawa, Ont.; Hôpital du Sacré-Cœur de Montréal (Samimi) and Colorectal Cancer Canada (Stein), Montréal, Que.; Department of Community Health and Epidemiology (Ramjeesingh), Dalhousie University, and Nova Scotia Cancer Care Centre (Ramjeesingh), Halifax, NS
Faculty of Nursing (Cuthbert, Daze, Farrer) and Department of Oncology, Cumming School of Medicine (Cuthbert, Nixon, Karim, Cheung), University of Calgary; Cancer Care Alberta (Nixon, Rawson, Karim, Cheung) and Patient and Family Engagement Advisory Network for Cancer Care Alberta (Laxdal, Huband), Alberta Health Services, Calgary, Alta.; Patient and Family Engagement Advisory Network for Cancer Care Alberta (Dundas), Alberta Health Services, Drumheller, Alta.; The Ottawa Hospital (Vickers) and University of Ottawa (Vickers), Ottawa, Ont.; Hôpital du Sacré-Cœur de Montréal (Samimi) and Colorectal Cancer Canada (Stein), Montréal, Que.; Department of Community Health and Epidemiology (Ramjeesingh), Dalhousie University, and Nova Scotia Cancer Care Centre (Ramjeesingh), Halifax, NS.
CMAJ Open. 2022 Mar 29;10(1):E278-E287. doi: 10.9778/cmajo.20210046. Print 2022 Jan-Mar.
Colorectal cancer, one of the most commonly diagnosed cancers, is now being detected earlier and treatments are improving, which means that patients are living longer. Partnering with Canadian clinicians, patients and researchers, we aimed to determine research priorities for those living with early-stage colorectal cancer in Canada.
We followed the well-established priority-setting partnership outlined by the James Lind Alliance to identify and prioritize unanswered questions about early-stage (i.e., stages I-III) colorectal cancer. The study was conducted from September 2018 to September 2020. We surveyed patients, caregivers and clinicians from across Canada between June 2019 and December 2019. We categorized the responses using thematic analysis to generate a list of unique questions. We conducted an interim prioritization survey from April 2020 to July 2020, with patients, caregivers and clinicians, to determine a shorter list of questions, which was then reviewed at a final meeting (involving patients, caregivers and clinicians) in September 2020. At that meeting, we used a consensus-based process to determine the top 10 priorities.
For the initial survey, 370 responses were submitted by 185 individuals; of the 98 individuals who provided demographic information, 44 (45%) were patients, 16 (16%) were caregivers, 7 (7%) were members of an advocacy group, 26 (27%) were health care professionals and 5 (5%) were categorized as "other." The responses were refined to create a list of 66 unique unanswered questions. Twenty-five respondents answered the interim prioritization survey: 13 patients (52%), 2 caregivers (8%), 3 advocacy group members (12%) and 7 health care professionals (28%). This led to a list of the top 30 questions. The final consensus meeting involved 20 individuals (10 patients [50%], 3 caregivers [15%] and 7 health care professionals [35%]), who agreed to the top 10 research priorities. The priorities covered a range of topics, including screening, treatment, recurrence, management of adverse effects and decision-making.
We determined the top research priorities for early-stage colorectal cancer using a collaborative partnership of stake-holders from across Canada. The priorities covered a broad range of topics that could be addressed by future research, including improved screening practices, the role of personalized medicine, the management of adverse effects of treatment, decision-making and prevention of recurrence.
结直肠癌是最常见的癌症之一，现在的早期诊断率更高，治疗也在改善，这意味着患者的寿命更长。我们与加拿大临床医生、患者和研究人员合作，旨在确定加拿大早期结直肠癌患者的研究重点。
我们遵循詹姆斯林德联盟（James Lind Alliance）制定的既定优先事项伙伴关系，以确定和优先考虑早期结直肠癌（即 I-III 期）的未解答问题。该研究于 2018 年 9 月至 2020 年 9 月进行。我们于 2019 年 6 月至 12 月期间对来自加拿大各地的患者、护理人员和临床医生进行了调查。我们使用主题分析对这些回复进行分类，以生成一份独特问题清单。我们于 2020 年 4 月至 7 月期间进行了一次中期优先级调查，涉及患者、护理人员和临床医生，以确定一份较短的问题清单，然后在 2020 年 9 月的一次最终会议上进行了审查（涉及患者、护理人员和临床医生）。在那次会议上，我们使用基于共识的流程确定了前 10 个优先事项。
在初始调查中，185 人提交了 370 份回复；在提供人口统计学信息的 98 人中，44 人（45%）是患者，16 人（16%）是护理人员，7 人（7%）是倡导组织成员，26 人（27%）是医疗保健专业人员，5 人（5%）被归类为“其他”。对这些回复进行了精炼，创建了一份 66 个独特的未解答问题清单。25 名受访者回答了中期优先级调查：13 名患者（52%）、2 名护理人员（8%）、3 名倡导组织成员（12%）和 7 名医疗保健专业人员（28%）。这导致了前 30 个问题清单的产生。最终的共识会议涉及 20 人（10 名患者[50%]、3 名护理人员[15%]和 7 名医疗保健专业人员[35%]），他们同意前 10 项研究重点。这些重点涵盖了一系列主题，包括筛查、治疗、复发、不良反应管理和决策。
我们使用来自加拿大各地的利益相关者的合作伙伴关系，确定了早期结直肠癌的研究重点。这些重点涵盖了广泛的主题，可以通过未来的研究来解决，包括改进筛查实践、个性化医疗的作用、治疗不良反应的管理、决策和复发预防。
